Erleada

Active Ingredient(s): Apalutamide
FDA Approved: * February 14, 2018
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Erleada Overview

Apalutamide, sold under the brand name Erleada, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer.[1][3] It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).[1][4][5] It is taken by mouth.[1][5] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, and diarrhea.[1][6][7][8] Rarely, it can cause seizures.[1] I...

Read more Erleada Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Apalutamide

Recent Erleada Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Apalutamide
  • Tablet: 60mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Erleada: (1 result)

Sorted by National Drug Code
  • 59676-600 Erleada 60 mg Oral Tablet, Film Coated by Janssen Products, Lp

Other drugs which contain Apalutamide or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 April 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.